Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • prognosFACTOR®
    • Marketplace
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey
      • Physician Segmentation
      • Outcomes
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
      • Risk Adjustment & Quality Analytics
  • Company
    • Careers
    • Events
    • News
    • Insights
  • Contact Us
Home Insights Comorbidity Between Diabetes and RA

Comorbidity Between Diabetes and RA

  • November 9, 2017
  • Posted in Disease Awareness

This post was last updated on December 2, 2019 at 9:42 pm

How is comorbidity affected by a double positive?

By Jason Bhan, MD, Fernando Schwartz, PhD, and Lauren Wiener>

If you read our previous blog, you know that Prognos has set out to prove that diabetes and rheumatoid arthritis are comorbid conditions.  In today’s blog we are ready to share our findings with our readers.

As a reminder, we hypothesized that our analysis would point to a comorbidity between diabetes and RA, and also set out to investigate whether patients with a double positive RA diagnosis would be affected by the presence of a diabetes comorbidity.  We searched the expansive Prognos Registry to find patients with diabetes and RA, as well as double positive RA patients (RF+ and anti-CCP+) and performed detailed analyses, including a chi square test, to find statistically significant differences between populations.

Study Results: Comorbidity

The Prognos Registry contains 24,252,264 patients with type 2 diabetes, and 2,114,010 patients with RA. Of these patients, 608,540 are comorbid and are diagnosed with both type 2 diabetes and RA. These results mean that 28.79% of RA patients have diabetes, which is a significant comorbidity, and is similar to the 31% reported in a research study with 340 RA patients. Our results also show that 2.51% of diabetes patients have RA, which is a striking comorbidity given that RA is absent from current standards of care guidelines for diabetes.

Screen Shot 2017-11-09 at 2.51.58 PM

The Prognos database currently has a total of over 175 million patients across all conditions. Of the patients in the database, 13.799% have diabetes and 1.203% have RA. If the two diseases were independent, 0.166% of patients in the database would have diabetes and RA. However, 0.346% of patients in the Prognos database were found to have both diabetes and RA. Our findings report a comorbidity between diabetes and RA with an unprecedented sample size.

Study Results: Double Positive Risk Factor

Of the 2,114,010 RA patients, 121,546 were found to have a double positive diagnosis, and 1,992,464 were found to not have a double positive diagnosis. The distribution of the double positive patients between the just RA and comorbid population are shown in the table below:

Screen Shot 2017-11-09 at 3.00.02 PM

We were surprised to find that a double positive diagnosis is more common in the population suffering solely from RA rather than the comorbid population. Both RA and diabetes are inflammatory diseases, so a double positive could be expected to be more common in a comorbid population.

Of the patients that had only RA, 5.977% had a double positive diagnosis, and 5.187% of comorbid patients had a double positive diagnosis. A chi-square test was performed, which resulted in a chi-square statistic of 499.165, a p value of 2.2e-16, and one degree of freedom. The null hypothesis for the chi-square test is that there is no difference between the two populations. This small p value means we can reject the null hypothesis. The RA-only and comorbid populations differ with respect to a double positive diagnosis with a high degree of certainty.

What’s to Come…

Next week we’ll wrap up with our thoughts on what this could all mean.  As always, we encourage you to follow along with us and to reach out to us at info@prognos.ai with questions or to request additional information.

Reading List

  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454807/
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810070/
  • http://ard.bmj.com/content/69/7/1292
  • http://onlinelibrary.wiley.com/doi/10.1002/art.11223/full
  • http://onlinelibrary.wiley.com/doi/10.1002/1529-0131(200001)43:1%3C155::AID-ANR20%3E3.0.CO;2-3/full
« Diabetes and Rheumatoid Arthritis: A Missing Link?
Diabetes and RA: Further Explanations for Comorbidity »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Omnichannel Marketing
  • Physician Segmentation
  • Prog Spotlight
  • Technology

Archives

Latest Tweets

Prognos HealthFollow

Prognos Health
prognosAIPrognos Health@prognosAI·
19 Feb

#HealthcareAnalytics are evolving.

On Tuesday February 23, Prognos Health co-founder and CEO, @sundeepbhan, will join @Safeguard for a virtual discussion on the healthcare data revolution with @GKurtzman.

Register: https://us02web.zoom.us/webinar/register/WN_WlCiq5v2TICwSMRi-PVGZw

#HealthcareData #prognosFACTOR

Reply on Twitter 1362875761674354689Retweet on Twitter 1362875761674354689Like on Twitter 1362875761674354689Twitter 1362875761674354689
prognosAIPrognos Health@prognosAI·
11 Feb

Find a way, or make a way. It’s the Prognos mantra embraced by Ali Koc, VP of Engineering at Prognos Health.

In his latest blog post, Ali writes about making data accessible at web speeds, and how it enables data analysis in a truly new way.

https://prognoshealth.com/blog/find-a-way-or-make-a-way-building-an-interactive-analytics-platform-that-speaks-healthcare/

#HealthTech

Reply on Twitter 1359933724088020994Retweet on Twitter 1359933724088020994Like on Twitter 13599337240880209942Twitter 1359933724088020994
prognosAIPrognos Health@prognosAI·
28 Jan

#TBT to our webinar featuring #LifeSciences thought leaders from @Novartis, @TakedaPharma, and @pfizer as well as Prognos Co-founder @jmbhan.

Our latest blog explores 9 insights from these experts for driving #Commercial #LaunchExcellence in #Pharma

https://prognoshealth.com/blog/overheard-at-the-reuters-health-webinar-9-insights-for-driving-commercial-launch-excellence/

Reply on Twitter 1354901342679146499Retweet on Twitter 1354901342679146499Like on Twitter 13549013426791464991Twitter 1354901342679146499
prognosAIPrognos Health@prognosAI·
22 Jan

Uncovering the (Clinical) Truth.

Bill Bowman and @olatulekan write about the intersection where #MachineLearning meets disease-specific #clinical knowledge - #ClinicalTruths - and how this improves #PatientOutcomes with #HealthcareAnalytics at scale.

https://prognoshealth.com/blog/uncovering-the-clinical-truth/

Reply on Twitter 1352709796135391237Retweet on Twitter 13527097961353912371Like on Twitter 13527097961353912373Twitter 1352709796135391237
prognosAIPrognos Health@prognosAI·
31 Dec

As we ring in the new year, there's so much to look forward to. We wish all of our clients, and partners a healthy, happy new year and are excited to continue innovating together in 2021 to positively impact care.

Reply on Twitter 1344647644669468672Retweet on Twitter 1344647644669468672Like on Twitter 13446476446694686722Twitter 1344647644669468672
Load More...
  • prognosFACTOR®
    • Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • Events
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2021. All Rights Reserved.

See What Decision Speed Looks Like in Action

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.